Thursday, June 7

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Léhar I+II

CHRONIC MYELOID LEUKEMIA

Chair: J. Goldman (Imperial College, London, United Kingdom)

• MOLECULAR BASIS OF ACTION OF 'THIRD GENERATION' TKI'S
  M. Deininger (OHSU, Portland, USA)
• MOLECULAR BASIS OF ACQUIRED RESISTANCE TO TKI'S
  H. Kantarjian (M.D. Anderson Cancer Center, Houston, USA) 
• NOT ALL TRANSFERASE INHIBITORS ARE EQUAL
  M. Copland (University of Glasgow, Glasgow, United Kingdom)

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Léhar III+IV

GRANULOCYTE AND MONOCYTE DISORDERS

Chair: J. Palmblad (Karolinska Institute, Stockholm, Sweden)

• THE USE OF G-CSF DURING TREATMENT OF LYMPHOMAS - THE EORTC GUIDELINES
  M. Schmidinger (Medical University of Vienna, Vienna, Austria)
• THE USE OF G-CSF IN MYELOID MALIGNANCIES
  U. Creutzig (University Children’s Hospital, Münster, Germany)
• MECHANISMS FOR AND CONSEQUENCES OF SEVERE CHRONIC NEUTROPENIA
  K. Welte (Medical School Hanover, Hanover, Germany)

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Stolz I

MULTIPLE MYELOMA

Chairs: P. Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands) H. Johnsen (Aalborg Hospital, Aalborg, Denmark)

• CLONAL EVOLUTION IN MULTIPLE MYELOMA
  S. Sahoto (University of Southampton, Southampton, United Kingdom)
• GENE EXPRESSION PROFILING OF THE MYELOMA STEM CELL
  B. Klein (INSERM, Montpellier, France)
• PROTEIN EXPRESSION PROFILING
  N. Bos (UMCG, Groningen, The Netherlands)
• IMMUNOPHENOTYPIC CHARACTERIZATION OF MYELOMATOUS PLASMA CELLS AND THEIR PRECURSORS: STRATEGIES BASED ON NORMAL B-CELL MUTATIONS PATTERNS
  A. Orfao (University of Salamanca, Salamanca, Spain)
• FUNCTIONAL CHARACTERIZATION OF PLASMABLASTS IN VITRO
  H. Johnsen (Aalborg Hospital, Aalborg, Denmark)
• ESTABLISHING A BIOBANK FOR MYELOMA STEM CELL RESEARCH
  D. Hose (University of Heidelberg, Heidelberg, Germany)

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Stolz II

MYELODYSPLASTIC SYNDROMES

Chairs: P. Fenaux (Hopital Avicenne, Paris, France) E. Hellström-Lindberg (Karolinska Institutet, Stockholm, Sweden)

• DETECTION OF GENETIC CHANGES IN MDS-CD34+ CELLS USING HIGH-RESOLUTION MOLECULAR TECHNIQUES
  D. Nowak (Charité, Berlin, Germany)
• MECHANISMS OF ACTION OF THE EGF-R INHIBITOR ERLOTINIB IN HIGH RISK MDS
  S. Boehrer (Institut Gustave Roussy, Paris, France)
• JAK-2 MUTATIONS IN SIDEROBLASTIC ANEMIA
  L. Malcovati (Haematologica, Pavia, Italy)
• UPDATE OF EORTC RESULTS WITH DECITABINE IN MDS, AND PRESENTATION OF A PREDICTIVE MODEL
  B. Ruter (University of Freiburg, Freiburg, Germany)
• DEBATE : HAS EPO TREATMENT AN IMPACT ON DISEASE PROGRESSION AND SURVIVAL IN LOW AND INT 1 RISK MDS?
  S. Park (Hopital Cochin, Paris, France) and L. Malcovati (Haematologica, Pavia, Italy)

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Schubert I

MYELOPROLIFERATIVE DISORDERS

Chair: H. Pahl (University Hospital Freiburg, Freiburg, Germany)

• MUTATED RAS AND BCL2 COOPERATE TO INDUCE LEUKEMIA IN A MICE
  C. Chomienne (Institute Universitaire d'Hematologie, Paris, France)
• EVALUATION OF THE ROLE OF HISTOLOGY IN ET DIAGNOSIS
  P. Campbell (Cambridge Institute for Medical Research, Cambridge, United Kingdom)
• MPL MUTATIONS IN MYELOPROLIFERATIVE DISORDERS
  M. Cazzola (University of Pavia Medical School, Pavia, Italy)
• DECREASED TRANSCRIPTION FACTOR FUNCTION AND MPD-LIKE SYNDROMES
  D. Tenen (Harvard Medical School, Boston, USA)

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Schubert II

QUALITY OF LIFE AND SYMPTOMS

Chair: C. Cleeland (M.D. Anderson Cancer Center, USA)

• A MULTI-NATIONAL SURVEY OF SYMPTOMS IN HEMATOLOGIC DISEASES: AIMS, HYPOTHESES, SCOPE, AVENUES OF FUNDING
  C. Cleeland (M.D. Anderson Cancer Center, USA)
• ON THE RESULTS OF THE MULTI-CENTER EPIDERMIOLOGICAL SYMPTOM STUDY IN ADVANCED CANCER PATIENTS IN RUSSIA
  T. Ionova (National Medical Surgical Center, St. Petersburg, Russia)
• CLINICAL PERSPECTIVES OF QOL AND SYMPTOM RESEARCH IN HEMATOLOGY
  A. Novik (National Medical Surgical Center, Moscow, Russia)
• PATIENT-REPORTED OUTCOME AND INFLAMMATORY BIOLOGICAL MARKERS: MDASI FOR ALLO-BMT IN A PERSPECTIVE STUDY
  S. Wang (M.D. Anderson Cancer Center, USA)
• QUALITY OF LIFE AND SYMPTOM MEASURES IN HEMATOLOGIC DISEASE
  F. Efficace (University "La Sapienza", Rome, Italy)

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Schubert III

THROMBOCYTOPENIAS

Chair: B. Godeau (CHU Henri Mondor, Paris, France) F. Rodeghiero (San Bartolo Hospital, Vicenza, Italy)

• INTRODUCTION
  B. Godeau (CHU Henri Mondor, Paris, France) K PHARMACOECONOMIC STUDIES AND ITP: A NEW CHALLENGE? D. Provan (GlaxoSmithKline, London, United Kingdom)
• HELICOBACTER PYLORI AND ITP: WHERE DO WE STAND?
  R. Stasi (Ospedale ‘Regina Apostolorum’, Albano Laziale, Italy)
• THROMBOCYTOPENIA AND ANTIPHOSPHOLIPID SYNDROME
  M. Michel (CHU Henri Mondor, Paris, France)
• WHEN FAMILIAL THROMBOCYTOPENIA SHOULD BE SUSPECTED?
  J. Viallard (Hôpital Haut-Lévêque, Bordeaux, France)
• PRELIMINARY STEPS TOWARDS A COMMON TERMINOLOGY IN ITP
  F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy)
• CONCLUSION AND NEW PROPOSALS

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Schubert IV

ESG-MRD-ALL

Chair: J. van Dongen (Erasmus Medical Center, Rotterdam, The Netherlands)

• IG/TCR MONITORING OF HIGH LEVEL MRD WITHIN THE GRAALL-2003 (LALA GOELAMS SAKK) ADULT ALL TRIAL
  E. Macintyre (Hopital Necker/Enfants Malades, Paris, France)
• CLINICAL SIGNIFICANCE OF MRD IN ADULT ALL
  T. Raff (University of Kiel, Kiel, Germany)
• IMPACT OF POST-TRANSPLANT MRD-DETECTION IN CHILDHOOD ALL
  H. Kreyenberg (Kinderklinik, Freiburg, Germany) and P. Bader (University Children's Hospital, Frankfurt, Germany)
• MRD DIAGNOSTICS IN INFANT ALL: COMPLEXITY AND CLINICAL RELEVANCE
  J. van Dongen / V. van der Velden (Erasmus Medical Center, Rotterdam, The Netherlands)

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Schubert V

PHARMACOKINETICS, PHARMACOGENETICS & PHARMACODYNAMICS

Chair: M. Hassan (Karolinska Institute of medicine, Stockholm, Sweden)

• ANTIVIRAL TOXICITY IN HEMATOLOGY PATIENTS (EXPERIENCE FROM ACICLOVIR AND GANCICLOVIR TREATMENT)
  A. Helldén (Karolinska University Hospital, Huddinge, Sweden)
• MECHANISMS OF ANTIFOLATE RESISTANCE AND METHOTREXATE EFFICACY IN LEUKAEMIA CELLS
  F. Albertioni (Karolinska Cancer Centre, Stockholm, Sweden)
• G-CSF IN HEALTHY DONORS: HOW SHOULD WE DOSE BY UG/KG OR UG/M2
  H. Hägglund (Karolinska University Hospital, Huddinge, Sweden)
• THE IMPORTANCE OF PHARMACOKINETICS AND SYSTEMIC EXPOSURE OF ALKYLATING AGENTS IN PRETRANSPLANT CONDITIONING THERAPY FOR AML/MDS
  B. Andersson (M.D. Anderson Cancer Center, USA)

SCIENTIFIC WORKING GROUP

18.30-19.45 hours, Room: Schubert VI

RED CELL AND IRON

Chair: Y. Beuzard (Hôpital Saint Louis, Paris, France)

• UNDERSTANDING HOW GENES ARE ACTIVATED AND REPRESSED DURING HAEMATOPOIESIS
  D. Higgs (John Radcliffe Hospital, Oxford, United Kingdom)
• GATA-1 FUNCTIONS IN ERYTHROID CELL DIFFERENTIATION AND IN DISEASE
  J. Strouboulis (Erasmus Medical Center, Rotterdam, The Netherlands)
• REGULATION OF mRNA TRANSLATION IN ERYTHROPOIESIS
  M. von Lindern (Erasmus Medical Center, Rotterdam, The Netherlands)
• NEW GENETIC DETERMINANTS OF FETAL HEMAGLOBIN EXPRESSION
  S.L. Thein (King's College Hospital, London, United Kingdom)